Innoviva’s Specialty Therapeutics Platform Hits $150M Revenue with 46% Growth
Innoviva has a $1.4 billion market cap, trading at a forward P/E of 10.83 after generating $400 million in annual revenue and $364 million in free cash flow from GSK royalties. Its Specialty Therapeutics platform now accounts for $150 million (40% of revenue) with 46% annual growth and high cash-flow leverage.
1. Historic Royalty Model
Innoviva earned roughly $400 million in annual revenue and $364 million in free cash flow from GSK-licensed royalties, trading at a trailing P/E of 13.54 and forward P/E of 10.83 before patents expire in 2029–2030.
2. Specialty Therapeutics Platform Growth
The Innoviva Specialty Therapeutics platform has scaled to $150 million in revenue, representing 40% of total revenue, with 46% year-over-year growth driven by hospital-based drugs including XACDURO and Zoliflodacin.
3. Valuation and Asymmetric Upside
With a $1.4 billion market cap valuing the royalty stream at about $1.35 billion, the Specialty Therapeutics platform is effectively priced at zero, creating significant upside if commercial growth continues.
4. Catalysts and Risks
Key catalysts include surpassing the $150 million breakeven threshold to achieve 60%+ free cash flow conversion and potential takeover interest, balanced against execution risks and dependency on GSK royalties until 2029.